Sunpharma Secure Settlement in U.S. Generic Drug Price

Sun Pharma Subsidiaries Secure Settlement in Major U.S. Generic Drug Price-Fixing Antitrust Litigation : - In a significant legal development aimed at clearing long-standing regulatory and litigation hurdles in its largest overseas market, Sun Pharmaceutical Industries Limited announced that its key North American subsidiaries have entered into a confidential settlement agreement. The deal effectively resolves a major subset of claims within the massive, multi-district litigation known as In re Generic Pharmaceuticals Pricing Antitrust Litigation, currently pending in the United States District Court for the Eastern District of Pennsylvania. The agreement involves three prominent arms of India's largest drugmaker: Sun Pharmaceutical Industries Inc. (SPII), Taro Pharmaceutical Industries Ltd., and Taro Pharmaceuticals U.S.A., Inc. While the exact financial terms and payout figures of the settlement remain strictly confidential under the provisions of the contract, the resolution marks a strategic milestone for the pharmaceutical giant as it systematically de-risks its corporate liabilities in the United States.